Page 1

PLX PHARMA INC . PLX Pharma Inc. Reports Second Quarter 2021 Results and Provides Business Update August 6 , 2021 --Walmart , Walgreens , Rite Aid , CVS and many other retailers placing VAZALORE on shelves later this month- --VAZALORE launch inventory manufactured and currently shipping to retailers across the country- SPARTA , N.J. , Aug. 06 , 2021 ( GLOBE NEWSWIRE ) PLx Pharma Inc. ( NASDAQ : PLXP ) ( " PLx " or the " Company " ) , a specialty pharmaceutical company focused on its clinically - validated and patent - protected PLxGuardTM drug delivery platform to provide more effective and safer products , with its lead products VAZALORETM 325 mg and VAZALORETM 81 mg ( referred to together as " VAZALORE " ) , announced today certain financial and operational results for the three and six months ended June 30 , 2021 . Highlights of , and certain events subsequent to , the second quarter of 2021 include : • Walmart , Walgreens , Rite Aid , and CVS among the leading retailers to reserve shelf space for all three SKUs of VAZALORE ; • Extensive distribution for VAZALORE in over 30,000 U.S. retail stores ; • Launched specialty field force to raise awareness amongst healthcare professionals ; • Continue to inform specialists through medical conferences , publications and continuing professional education events ; and • VAZALORE launch inventory manufactured and currently shipping to retailers across the country . " We are continuing to execute on our commercial strategy with retailers , professionals and consumers , " stated Natasha Giordano , President and Chief Executive Officer of PLx . " We recently deployed our cardiovascular field force to raise awareness amongst specialists and now have sufficient inventory shipping to retailers to fulfill this widespread distribution . " " Keeping the patient top of mind has always been our guiding principle and we are excited to bring VAZALORE to millions of patients at risk , " concluded Giordano . Second Quarter 2021 Financial Results The Company recognized no revenue for the second quarter of 2021 compared to $ 27,907 for the second quarter of 2020. All the revenue recognized in the 2020 period was attributable to work performed under an award of a National Institutes of Health ( “ NIH ” ) grant , which came to an end in the second quarter of 2020 . Research and development expenses were $ 1.0 million for the second quarter of 2021 , compared to $ 1.4 million in the second quarter of 2020. This decrease is primarily attributable to lower pre - commercial manufacturing - related activities for VAZALORE and the non - recurrence of clinical - related spending for the bioequivalence study in 2020 . Selling , marketing and administrative expense totaled $ 5.5 million in the second quarter of 2021 compared to $ 2.2 million in the second quarter of 2020. This increase primarily reflects higher sales and marketing expenses to prepare for the VAZALORE launch and increased non - cash stock - based compensation . Other expense totaled $ 10.0 million in the second quarter of 2021 compared to $ 2.0 million in the second quarter of 2020. The increase is largely attributable to the non - cash change in fair value of warrant liability primarily due to the fluctuation of the price of the Company's common stock combined with lower net interest due to the payoff of the term loan with Silicon Valley Bank in February 2021 . Net loss attributable to common stockholders for the second quarter of 2021 was $ 18.7 million , or ( $ 0.79 ) per basic and diluted share , compared $ 6.0 million , or ( $ 0.66 ) per basic and diluted share , for the second quarter of 2020. The second quarter of 2021 included a non - cash loss of $ 10.0 million , or ( $ 0.42 ) per share , related to the change in fair value of warrant liability versus a non - cash loss of $ 1.9 million , or ( $ 0.21 ) per share for the second quarter of 2020. The second quarter of 2021 also included $ 2.2 million or ( $ 0.09 ) per share for the beneficial conversion feature related to the conversion of Series A convertible preferred stock dividends . The second quarter of 2020 included $ 0.4 million , or ( $ 0.04 ) per share , for dividends on the Series A and Series B convertible preferred stock . All convertible preferred stock dividends stopped accruing upon U.S. Food and Drug Administration ( " FDA " ) approval of VAZALORE in first quarter of 2021 . First Half 2021 Financial Results For the six months ended June 30 , 2021 , the Company recognized no revenue compared to $ 30,430 in the comparable period in 2020. All the revenue recognized in the 2020 period was attributable to work performed under an award of an NIH grant , which concluded in the second quarter of 2020 . Research and development expense was $ 1.9 million for the six months ended June 30 , 2021 and for the comparable 2020 period . Research and development expenses primarily reflect pre - commercial manufacturing - related activities for VAZALORE and 2020 included costs related to the